In plain language
Sermorelin is a shortened, active fragment of growth hormone releasing hormone (the first 29 amino acids) that stimulates the pituitary to make growth hormone. It was once an approved medicine for diagnosing and treating certain growth problems before being withdrawn from the US market. Evidence for the uses it is now marketed for is limited.
What it is explored for
Sermorelin has a long and credible backstory: it was once an approved medicine and works by encouraging the pituitary to produce growth hormone in a natural, pulsing pattern. That gentle, body-led approach, often paired with Ipamorelin, is why it remains a mainstay in healthy-aging conversations. Here is where interest and reported use are highest.
- Supporting the body's own growth-hormone release
- Recovery and tissue repair
- Lean muscle, strength, and maintenance
- Better sleep quality
- Energy and daily vitality
- Skin quality and collagen support
- Healthy aging
- Focus and mental clarity
These are areas of active interest and reported use, not proven outcomes. This peptide carries a limited evidence rating, see the evidence summary below for how strong the science actually is.
How it works
Sermorelin reproduces the active portion of natural GHRH, signaling the pituitary to release growth hormone in a pulsatile, physiological pattern.
- GHRH receptor activation. Binds pituitary GHRH receptors to stimulate endogenous growth hormone release.
- Preserved feedback. Because it works through the pituitary rather than replacing GH directly, normal negative feedback remains in place.
- Downstream IGF-1. Released growth hormone raises circulating IGF-1, the mediator of many GH effects.
Mechanistic data is well established for GH release; evidence for many currently marketed anti-aging and body-composition uses is limited.
Evidence summary
Sermorelin has a clearer regulatory history than most peptides here, having been approved for diagnostic testing of GH reserve and for pediatric growth hormone deficiency before withdrawal. However, evidence for the wellness and anti-aging uses it is now marketed for is limited, and modern controlled outcome trials in those settings are scarce.
Reported safety & side effects
During its approved use, sermorelin was generally well-tolerated, with injection-site reactions, flushing, and headache reported most often. Long-term safety in current off-label wellness contexts is less well characterized.
Stacking notes
Full stacking guideA GHRH analog plus a growth-hormone-releasing peptide, the classic two-pathway approach to a stronger, more natural GH pulse than either alone.
GHRP-2MK-677 already raises growth hormone and IGF-1 strongly on its own. Adding another secretagogue compounds water retention, appetite, and insulin-resistance effects for little clear added benefit.
MK-677IpamorelinTwo peptides that both act as GHRH analogs are redundant. One occupies the same receptor the other would, so the combination adds cost and variables, not effect.
CJC-1295General educational guidance, not medical advice. Combination evidence is limited; any stack should involve a qualified clinician.
Frequently asked
Is sermorelin FDA-approved?
It was historically approved as Geref for diagnostic testing of growth hormone reserve and for pediatric growth hormone deficiency, but it was later withdrawn from the US market and is not currently an approved medicine. Today it is often compounded and used off-label.
How does sermorelin differ from synthetic HGH?
Synthetic HGH (somatropin) replaces growth hormone directly. Sermorelin instead stimulates the pituitary to make its own GH, which preserves the body's normal feedback and pulsatile release pattern.
Is there good evidence for anti-aging use?
Not robustly. While GH-releasing activity is well documented, controlled human trials supporting anti-aging or body-composition claims are limited.